Neumora Therapeutics (NMRA) Change in Accured Expenses (2022 - 2026)

Neumora Therapeutics' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 339.43% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 111.54% YoY), while the FY2025 annual figure was $4.2 million, down 42.03% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $4.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $7.6 million in Q3 2024, with the low at -$6.3 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $1.9 million (2024), against an average of $1.5 million.
• Peak annual rise in Change in Accured Expenses reached 184.95% in 2024, while the deepest fall reached 458.83% in 2024.
• Neumora Therapeutics' Change in Accured Expenses stood at $7.0 million in 2022, then sank by 130.73% to -$2.2 million in 2023, then surged by 184.95% to $1.8 million in 2024, then jumped by 116.89% to $4.0 million in 2025, then plunged by 201.01% to -$4.0 million in 2026.
• Business Quant data shows NMRA's Change in Accured Expenses at -$4.0 million in Q1 2026, $4.0 million in Q4 2025, and $4.9 million in Q3 2025.